Expanding Immunology And Neuroscience Will Reshape Global Healthcare

Published
17 Jul 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$214.77
3.8% undervalued intrinsic discount
14 Aug
US$206.57
Loading
1Y
4.9%
7D
4.0%

Author's Valuation

US$214.8

3.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Increased 2.03%

Shared on30 Apr 25
Fair value Decreased 0.58%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 1.55%

AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to 0.0%.

Shared on16 Apr 25
Fair value Decreased 0.037%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 2.88%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 1.41%

Shared on26 Mar 25
Fair value Increased 0.23%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 3.15%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Decreased 5.32%

AnalystConsensusTarget has increased revenue growth from 6.2% to 7.0% and increased shares outstanding growth rate from -0.0% to 0.0%.